General Thoracic and Cardiovascular Surgery

, Volume 66, Issue 4, pp 192–200 | Cite as

Septal myectomy for hypertrophic cardiomyopathy: important surgical knowledge and technical tips in the era of increasing alcohol septal ablation

  • Yuting P. Chiang
  • Yuichi J. Shimada
  • Jonathan Ginns
  • Shepard D. Weiner
  • Hiroo TakayamaEmail author
Current Topics Review Article


Hypertrophic cardiomyopathy (HCM) is the most commonly inherited cardiac disease—recent studies suggest a prevalence as high as 1 in 200. For symptomatic patients with obstructive HCM who are refractory to medical therapy, septal reduction is indicated. Septal myectomy (SM) is considered the gold standard septal reduction technique. However, due to a shortage of surgeons who are experienced in this technique, alcohol septal ablation (ASA) has overtaken SM as the most commonly performed procedure for obstructive HCM. In this review, we summarize the existing literature comparing SM with ASA and describe recent innovations in operative technique, including a detailed description of the approach used at our institution.


Hypertrophic cardiomyopathy Septal myectomy Alcohol septal ablation 


Compliance with ethical standards

Conflict of interest

Dr. Chiang has no conflicts of interest to disclose. Dr. Shimada has no conflicts of interest to disclose. Dr Ginns has no conflicts of interest to disclose. Dr Weiner has no conflicts of interest to disclose. Dr Takayama has no conflicts of interest to disclose.

Supplementary material

Supplementary material 1 (M4V 107315 KB)


  1. 1.
    Semsarian C, Ingles J, Maron M, Maron M. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65(12):1249–54.CrossRefPubMedGoogle Scholar
  2. 2.
    Maron BJ, Dearani JA, Ommen SR, Maron MS, Schaff HV, Nishimura RA, et al. Low operative mortality achieved with surgical septal myectomy: role of dedicated hypertrophic cardiomyopathy centers in the management of dynamic subaortic obstruction. J Am Coll Cardiol. 2015;66(11):1307–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Takayama H, Chung WK, Maurer MS, Ginns JN. Hypertrophic cardiomyopathy: new approaches and a time to reappraise older approaches. J Thorac Cardiovasc Surg. 2016;152(4):983–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Sen-Chowdhry S, Jacoby D, Moon JC, McKenna WJ. Update on hypertrophic cardiomyopathy and a guide to the guidelines. Nat Rev Cardiol. 2016;13(11):651–75.CrossRefPubMedGoogle Scholar
  5. 5.
    Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2011;58(25):2703–38.CrossRefPubMedGoogle Scholar
  6. 6.
    Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. Eur Heart J. 2014;35(39):2733–79.CrossRefPubMedGoogle Scholar
  7. 7.
    Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res. 2017;121(7):749–70.CrossRefPubMedGoogle Scholar
  8. 8.
    Burke MA, Cook SA, Seidman JG, Seidman CE. Clinical and mechanistic insights into the genetics of cardiomyopathy. J Am Coll Cardiol. 2016;68(25):2871–86.CrossRefPubMedCentralPubMedGoogle Scholar
  9. 9.
    Maron BJ, Semsarian C. Emergence of gene mutation carriers and the expanding disease spectrum of hypertrophic cardiomyopathy. Eur Heart J. 2010;31(13):1551–3.CrossRefPubMedGoogle Scholar
  10. 10.
    Ho C. Is genotype clinically useful in predicting prognosis in hypertrophic cardiomyopathy? Circulation. 2010;122:2450.CrossRefGoogle Scholar
  11. 11.
    McTaggart DR, Ogden KJ, Marathe JA. A long term follow-up study of carriers of hypertrophic cardiomyopathy mutations. Heart Lung Circ. 2017;26(1):18–24.CrossRefPubMedGoogle Scholar
  12. 12.
    Ho CY, McMurray JJV, Cirino AL, Colan SD, Day SM, Desai AS, et al. The design of the valsartan for attenuating disease evolution in early sarcomeric hypertrophic cardiomyopathy (VANISH) trial. Am Heart J. 2017;187:145–55.CrossRefPubMedCentralPubMedGoogle Scholar
  13. 13.
    Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, Kuvin JT, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation. 2006;114(21):2232–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Ommen SR, Shah PM, Tajik AJ. Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy: past, present and future. Heart. 2008;94:1276–81.CrossRefPubMedGoogle Scholar
  15. 15.
    Maron MS, Maron BJ, Harrigan C, Buros J, Gibson CM, Olivotto I, et al. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. J Am Coll Cardiol. 2009;54(3):220–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Klues HG, Maron BJ, Dollar AL, Roberts WC. Diversity of structural mitral alterations in hypertrophic cardiomyopathy. Circulation. 1992;85(5):1651–60.CrossRefPubMedGoogle Scholar
  17. 17.
    Klues HG, Roberts WC, Maron BJ. Morphological determinants of echocardiographic patterns of mitral valve systolic anterior motion in obstructive hypertrophic cardiomyopathy. Circulation. 1993;87(5):1570–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Kaple RK, Murphy RT, DiPaola LM, Houghtaling PL, Lever HM, Lytle BW, et al. Mitral valve abnormalities in hypertrophic cardiomyopathy: echocardiographic features and surgical outcomes. Ann Thorac Surg. 2008;85(5):1527–35.CrossRefPubMedGoogle Scholar
  19. 19.
    Sherrid MV, Balaram S, Kim B, Axel L, Swistel DG. The mitral valve in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2016;67(15):1846–58.CrossRefPubMedGoogle Scholar
  20. 20.
    Maron BJ, Nishimura RA. Surgical septal myectomy versus alcohol septal ablation: assessing the status of the controversy in 2014. Circulation. 2014;130(18):1617–24.CrossRefPubMedGoogle Scholar
  21. 21.
    Fifer MA. Controversies in cardiovascular medicine. Most fully informed patients choose septal ablation over septal myectomy. Circulation. 2007;16:207–16.CrossRefGoogle Scholar
  22. 22.
    Desai MY, Bhonsale A, Smedira NG, Naji P, Thamilarasan M, Lytle BW, et al. Predictors of long-term outcomes in symptomatic hypertrophic obstructive cardiomyopathy patients undergoing surgical relief of left ventricular outflow tract obstruction. Circulation. 2013;128(3):209–16.CrossRefPubMedGoogle Scholar
  23. 23.
    Nagueh SF, Groves BM, Schwartz L, Smith KM, Wang A, Bach RG, et al. Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2011;58(22):2322–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Sorajja P, Valeti U, Nishimura RA, Ommen SR, Rihal CS, Gersh BJ, et al. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation. 2008;118(2):131–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Vriesendorp PA, Liebregts M, Steggerda RC, Schinkel AF, Willems R, Ten Cate RJ, et al. Long-term outcomes after medical and invasive treatment in patients with hypertrophic cardiomyopathy. JACC Heart Fail. 2014;2(6):630–6.CrossRefPubMedGoogle Scholar
  26. 26.
    Liebregts M, Vriesendorp PA, Mahmoodi BK, Schinkel AF, Michels M, ten Berg JM. A systematic review and meta-analysis of long-term outcomes after septal reduction therapy in patients with hypertrophic cardiomyopathy. JACC Heart Fail. 2015;3(11):896–905.CrossRefPubMedGoogle Scholar
  27. 27.
    Ommen SR, Maron BJ, Olivotto I, Maron MS, Cecchi F, Betocchi S, et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;46(3):470–6.CrossRefPubMedGoogle Scholar
  28. 28.
    Kim LK, Swaminathan RV, Looser P, Minutello RM, Wong SC, Bergman G, et al. Hospital volume outcomes after septal myectomy and alcohol septal ablation for treatment of obstructive hypertrophic cardiomyopathy: US Nationwide Inpatient Database, 2003–2011. JAMA Cardiol. 2016;1(3):324–32.CrossRefPubMedGoogle Scholar
  29. 29.
    Liebregts M, Faber L, Jensen MK, Vriesendorp PA, Januska J, Krejci J, et al. Outcomes of alcohol septal ablation in younger patients with obstructive hypertrophic cardiomyopathy. JACC Cardiovasc Interv. 2017;10(11):1134–43.CrossRefPubMedGoogle Scholar
  30. 30.
    Morrow AG, Reitz BA, Epstein SE, Henry WL, Conkle DM, Itscoitz SB, et al. Operative treatment in hypertrophic subaortic stenosis. Circulation. 1975;52(1):88–102.CrossRefPubMedGoogle Scholar
  31. 31.
    Schaff HV, Said SM. Transaortic extended septal myectomy for hypertrophic cardiomyopathy. Op Tech Thorac Cardiovasc Surg. 2012;17(4):238–50.CrossRefGoogle Scholar
  32. 32.
    Fukuhara S, Edwards S, Kurlansky P, Takayama H. Bimanual examination for septal myectomy for hypertrophic cardiomyopathy. Interact Cardiovasc Thorac Surg. 2014;19(5):735–7.CrossRefPubMedGoogle Scholar
  33. 33.
    Balaram SK, Sherrid MV, Derose JJ, Hillel Z, Winson G, Swistel DG. Beyond extended myectomy for hypertrophic cardiomyopathy: the resection-plication-release repair. Ann Thorac Surg. 2005;80(1):217–23.CrossRefPubMedGoogle Scholar
  34. 34.
    Quintana E, Schaff HV, Dearani JA. Transapical myectomy for septal hypertrophy not accessible through the aortic root. World J Pediatr Congenit Heart Surg. 2015;6(3):455–7.CrossRefPubMedGoogle Scholar
  35. 35.
    Kotkar KD, Said SM, Dearani JA, Schaff HV. Hypertrophic obstructive cardiomyopathy: the Mayo Clinic experience. Ann Cardiothorac Surg. 2017;6(4):329–36.CrossRefPubMedCentralPubMedGoogle Scholar
  36. 36.
    Maron BJ, McIntosh CL, Klues HG, Cannon RO 3rd, Roberts WC. Morphologic basis for obstruction to right ventricular outflow in hypertrophic cardiomyopathy. Am J Cardiol. 1993;71(12):1089–94.CrossRefPubMedGoogle Scholar
  37. 37.
    Maron MS, Hauser TH, Dubrow E, Horst TA, Kissinger KV, Udelson JE, et al. Right ventricular involvement in hypertrophic cardiomyopathy. Am J Cardiol. 2007;100(8):1293–8.CrossRefPubMedGoogle Scholar
  38. 38.
    Borisov KV. Surgical correction of hypertrophic obstructive cardiomyopathy in patients with simultaneous obstruction of left ventricular midcavity and right ventricular outflow tract. Eur J Cardiothorac Surg. 2013;43(1):67–72.CrossRefPubMedGoogle Scholar
  39. 39.
    Quintana E, Johnson JN, Sabate-Rotes A, Cetta F, Ommen SR, Schaff HV, et al. Surgery for biventricular obstruction in hypertrophic cardiomyopathy in children and young adults: technique and outcomes. Eur J Cardiothorac Surg. 2015;47(6):1006–12.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Association for Thoracic Surgery 2018

Authors and Affiliations

  • Yuting P. Chiang
    • 1
  • Yuichi J. Shimada
    • 2
  • Jonathan Ginns
    • 2
  • Shepard D. Weiner
    • 2
  • Hiroo Takayama
    • 1
    Email author
  1. 1.Division of Cardiothoracic and Vascular Surgery, Department of SurgeryColumbia University Medical CenterNew YorkUSA
  2. 2.Division of Cardiology, Department of MedicineColumbia University Medical CenterNew YorkUSA

Personalised recommendations